We provide patients with:

- access to world leaders in bladder cancer surgery, medical oncology, radiation oncology, and nursing
- the benefit of seeing several dedicated bladder cancer specialists on one day, at one location
- the latest minimally invasive, image-guided techniques for diagnosis and treatment
- bladder preservation in selected patients with invasive cancer
- an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
- access to innovative clinical trials of new therapies, surgical techniques, and advanced technologies not available at other hospitals
- genomic sequencing for all patients to look for actionable mutations

LOCATIONS
Many of MSK’s specialists are centrally located in Manhattan. There are also MSK’s regional outpatient locations:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, New York

REFER A PATIENT
Contact the Physician Access Service directly at
800-525-2225
MSK has insurance contracts with most major health plans in the New York tristate area.

BLADDER CANCER PROGRAM OVERVIEW
MSK’s urologic cancer program is recognized as one of the world’s finest, ranked fifth out of 51 top-scoring hospitals for urology in U.S. News & World Report.

We provide patients with:

- access to world leaders in bladder cancer surgery, medical oncology, radiation oncology, and nursing
- the benefit of seeing several dedicated bladder cancer specialists on one day, at one location
- the latest minimally invasive, image-guided techniques for diagnosis and treatment
- bladder preservation in selected patients with invasive cancer
- an individualized treatment plan, comprehensive risk assessment, and long-term surveillance program
- access to innovative clinical trials of new therapies, surgical techniques, and advanced technologies not available at other hospitals
- genomic sequencing for all patients to look for actionable mutations

LOCATIONS
Many of MSK’s specialists are centrally located in Manhattan. There are also MSK’s regional outpatient locations:

- MSK Basking Ridge, New Jersey
- MSK Bergen, New Jersey
- MSK Monmouth, New Jersey
- MSK Commack, New York
- MSK Rockville Centre, New York
- MSK Westchester, New York

Our Team Leaders
Jonathan Rosenberg, MD
Chief, Genitourinary Medical Oncology Service, Division of Solid Tumor Oncology; Enno W. Ercklentz Chair

Victor Reuter, MD
Vice Chair, Department of Pathology; Director, Genitourinary Pathology; Director, Genitourinary Pathology Fellowship; Director, Pathology Core Facility

Alvin Goh, MD
Director, Robotic Urologic Surgery Technology and Education

Dean Bajorin, MD
Frederick R. Adler Senior Faculty Chair

Bernard Bochner, MD, FACS
Sir Murray F. Brennan Chair in Surgery

Guido Dalbagni, MD
Urologic Surgeon

S. Machele Donat, MD, FACS
Urologic Surgeon

Harry Herr, MD, FACS
Urologic Surgeon

David Solit, MD
Geoffrey Beene Chair; Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology

Sign up for OncoNotes, MSK’s clinical updates newsletter.

Go to MSKCC.org, click on the For Health Professionals section, and choose “Sign Up for Our E-newsletter.”
WHY CHOOSE MSK FOR BLADDER CANCER CARE?

Leadership

• Our surgeons participate in establishing the latest national guidelines for surgery, reconstruction, and surgical care.

• We completed the only properly powered randomized clinical study investigating the use of robotic technology for bladder removal.

• We have more than 23 bladder cancer clinical trials underway for a range of targeted therapies, immunotherapies, and novel surgical approaches. Our oncologists are leading many of the latest national trials for cutting-edge targeted chemotherapies and immunotherapies.

• Working with our world-class geneticists, we are leading the genetic investigations that will shape the future of treatment for urothelial tumors.

Advanced Technologies

• MSK is one of a few centers in the world providing robotic cystectomy and completely intracorporeal bladder reconstruction in the same operation for selected cases.

• We routinely utilize MSK-IMPACT™, a genome-sequencing test developed at MSK that quickly determines if tumors have actionable mutations using available targeted therapies or if patients may benefit from clinical trials.

• We offer neoadjuvant chemotherapy targeted to the genomic profile of patients’ individual cancers.

Expertise

• Our surgeons are among the most experienced in the world at performing radical cystectomy and have pioneered pelvic lymph node dissection to reduce the risk of cancer recurrence.

• We have extensive experience with successful urinary tract reconstruction in men and women to preserve natural voiding.

• We routinely employ sexual function-sparing surgery to help patients maintain intimacy after bladder removal surgery.

By the Numbers

7 locations

200 cystectomies performed per year and 1,200 cystoscopies and transurethral resections of bladder tumors performed in 2017

7 bladder cancer surgeons